Mannarini L, Bertino G, Morbini P, Villa C, Benazzo M
Department of Otolaryngology HN Surgery, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Acta Otorhinolaryngol Ital. 2007 Aug;27(4):173-80.
The onset of chemo- and/or radio-resistance in tumour cells is one of the main causes of failure of integrated treatment protocols combining intra-arterial administration of platinum derivatives and radiotherapy, and is associated with recurrent disease and/or distant metastases. In the present study, the expression of a series of markers of chemo- and/or radio-resistance was investigated in 21 patients with advanced squamous cell carcinoma of the head and neck treated with combined intra-arterial carboplatin and radiotherapy. The results were correlated with local response to treatment, recurrence and overall and disease-free survival. In non-responders or in patients presenting recurrence, caspase 8 was significantly (p 0.05) under-expressed while p-Gp (p 0.035) and MDR-3 (p 0.049) were significantly over-expressed. Tumours with unfavourable outcome more frequently over-expressed two or more anti-apoptotic factors (p-53, BCL-2, BCL-x) (p 0.01). Patients with shorter overall survival, significantly overexpressed p53 (p 0.04), LRP (p 0.038) and a larger number of trans-membrane transport proteins compared with those who survived more than one year (p 0.013). Finally, patients with the shortest disease-free survival presented over-expression of p53 (p 0.027) and BCL-x (p 0.023). Further studies are necessary to confirm the possibility, in a future perspective, of using a panel of markers of chemo- and radio-resistance to identify those patients potentially sensitive to the treatment and to avoid patients at high risk of resistance from being submitted to ineffective and toxic treatment protocols.
肿瘤细胞中化学抗性和/或放射抗性的出现是联合动脉内给予铂类衍生物和放射治疗的综合治疗方案失败的主要原因之一,并且与疾病复发和/或远处转移相关。在本研究中,对21例接受动脉内卡铂联合放疗的晚期头颈部鳞状细胞癌患者,研究了一系列化学抗性和/或放射抗性标志物的表达情况。结果与局部治疗反应、复发情况以及总生存期和无病生存期相关。在无反应者或出现复发的患者中,半胱天冬酶8显著低表达(p<0.05),而P-糖蛋白(p<0.035)和多药耐药蛋白3(p<0.049)显著高表达。预后不良的肿瘤更频繁地高表达两种或更多种抗凋亡因子(p53、BCL-2、BCL-x)(p<0.01)。与生存期超过一年的患者相比,总生存期较短的患者p53(p<0.04)、肺耐药蛋白(p<0.038)显著高表达,且跨膜转运蛋白数量更多(p<0.013)。最后,无病生存期最短的患者p53(p<0.027)和BCL-x(p<0.023)高表达。有必要进行进一步研究,以确认从未来角度使用一组化学抗性和放射抗性标志物来识别那些可能对治疗敏感的患者,并避免使有高耐药风险的患者接受无效和有毒的治疗方案的可能性。